Breaking News, Collaborations & Alliances

Turgut Ilaclari and Selexis Team Up

Sign service and commercial agreements to progress development of biosimilar products

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Mammalian cell line generation company Selexis SA and Turgut Ilaclari A.S., a biosimilar developer based in Turkey, have entered into a service agreement that provides Turgut with access to Selexis SUREtechnology Platform and SURE CHO-M Cell Line for the development of quality biosimilar products for the treatment of inflammatory diseases, certain cancers and two rare diseases. “Our scientists, inspired by the innovation of our technology, are driven to provide high performance, cost-effectiv...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters